DF-003 by Drug Farm for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData's report assesses how DF-003's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.DF-003 overviewDF-003 is under development for the treatment of rare blindness (ROSAH syndrome) and cardio-renal disease, chronic kidney disease (chronic renal failure). It is administered through oral route in the form of capsules. It acts by targeting alpha-protein kinase 1 (ALPK1) and is being developed based on IDInVivo technology.Drug Farm overviewDrug Farm developing innovative treatments targeting the innate immunity for hepatitis B, cancer, and autoimmune diseases. It is headquartered in Shanghai, China. For a complete picture of DF-003's drug-specific PTSR and LoA scores, buy the report here.
DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure).
What's Your Reaction?
